67 related articles for article (PubMed ID: 20129791)
1. 3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. part 2: optimization of the side chains to improve in vitro and in vivo potencies.
Asada M; Iwahashi M; Obitsu T; Kinoshita A; Nakai Y; Onoda T; Nagase T; Tanaka M; Yamaura Y; Takizawa H; Yoshikawa K; Sato K; Narita M; Ohuchida S; Nakai H; Toda M
Bioorg Med Chem; 2010 Feb; 18(4):1641-58. PubMed ID: 20129791
[TBL] [Abstract][Full Text] [Related]
2. 3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. Part 1: discovery and exploration of the carboxyamide side chain.
Asada M; Obitsu T; Nagase T; Tanaka M; Yamaura Y; Takizawa H; Yoshikawa K; Sato K; Narita M; Ohuchida S; Nakai H; Toda M
Bioorg Med Chem; 2010 Jan; 18(1):80-90. PubMed ID: 20004584
[TBL] [Abstract][Full Text] [Related]
3. 3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. Part 3: Synthesis, metabolic stability, and biological evaluation of optically active analogs.
Asada M; Obitsu T; Kinoshita A; Nagase T; Yoshida T; Yamaura Y; Takizawa H; Yoshikawa K; Sato K; Narita M; Nakai H; Toda M; Tobe Y
Bioorg Med Chem; 2010 May; 18(9):3212-23. PubMed ID: 20385498
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel N-acylsulfonamide analogs as potent and selective EP3 receptor antagonists.
Asada M; Obitsu T; Kinoshita A; Nakai Y; Nagase T; Sugimoto I; Tanaka M; Takizawa H; Yoshikawa K; Sato K; Narita M; Ohuchida S; Nakai H; Toda M
Bioorg Med Chem Lett; 2010 Apr; 20(8):2639-43. PubMed ID: 20346663
[TBL] [Abstract][Full Text] [Related]
5. Further optimization of sulfonamide analogs as EP1 receptor antagonists: synthesis and evaluation of bioisosteres for the carboxylic acid group.
Naganawa A; Matsui T; Ima M; Saito T; Murota M; Aratani Y; Kijima H; Yamamoto H; Maruyama T; Ohuchida S; Nakai H; Toda M
Bioorg Med Chem; 2006 Nov; 14(21):7121-37. PubMed ID: 16879970
[TBL] [Abstract][Full Text] [Related]
6. Peri-substituted hexahydro-indolones as novel, potent and selective human EP3 receptor antagonists.
O'Connell M; Zeller W; Burgeson J; Mishra RK; Ramirez J; Kiselyov AS; Andrésson T; Gurney ME; Singh J
Bioorg Med Chem Lett; 2009 Feb; 19(3):778-82. PubMed ID: 19121942
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a series of acrylic acids and their derivatives as chemical leads for selective EP3 receptor antagonists.
Asada M; Obitsu T; Nagase T; Sugimoto I; Yamaura Y; Sato K; Narita M; Ohuchida S; Nakai H; Toda M
Bioorg Med Chem; 2009 Sep; 17(18):6567-82. PubMed ID: 19700331
[TBL] [Abstract][Full Text] [Related]
8. Discovery of new chemical leads for selective EP1 receptor antagonists.
Naganawa A; Saito T; Nagao Y; Egashira H; Iwahashi M; Kambe T; Koketsu M; Yamamoto H; Kobayashi M; Maruyama T; Ohuchida S; Nakai H; Kondo K; Toda M
Bioorg Med Chem; 2006 Aug; 14(16):5562-77. PubMed ID: 16697646
[TBL] [Abstract][Full Text] [Related]
9. 3-Acrylamide-4-aryloxyindoles: synthesis, biological evaluation and metabolic stability of potent and selective EP3 receptor antagonists.
Zhou N; Zeller W; Zhang J; Onua E; Kiselyov AS; Ramirez J; Palsdottir G; Halldorsdottir G; Andrésson T; Gurney ME; Singh J
Bioorg Med Chem Lett; 2009 Mar; 19(5):1528-31. PubMed ID: 19188065
[TBL] [Abstract][Full Text] [Related]
10. Discovery of heteroaryl sulfonamides as new EP1 receptor selective antagonists.
Naganawa A; Matsui T; Saito T; Ima M; Tatsumi T; Yamamoto S; Murota M; Yamamoto H; Maruyama T; Ohuchida S; Nakai H; Kondo K; Toda M
Bioorg Med Chem; 2006 Oct; 14(19):6628-39. PubMed ID: 16784865
[TBL] [Abstract][Full Text] [Related]
11. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
Henke BR; Blanchard SG; Brackeen MF; Brown KK; Cobb JE; Collins JL; Harrington WW; Hashim MA; Hull-Ryde EA; Kaldor I; Kliewer SA; Lake DH; Leesnitzer LM; Lehmann JM; Lenhard JM; Orband-Miller LA; Miller JF; Mook RA; Noble SA; Oliver W; Parks DJ; Plunket KD; Szewczyk JR; Willson TM
J Med Chem; 1998 Dec; 41(25):5020-36. PubMed ID: 9836620
[TBL] [Abstract][Full Text] [Related]
12. 1,5-Biaryl pyrrole derivatives as EP1 receptor antagonists: Structure-activity relationships of 4- and 5-substituted benzoic acid derivatives.
Hall A; Brown SH; Chessell IP; Chowdhury A; Clayton NM; Coleman T; Giblin GM; Hammond B; Healy MP; Johnson MR; Metcalf A; Michel AD; Naylor A; Novelli R; Spalding DJ; Sweeting J
Bioorg Med Chem Lett; 2007 Feb; 17(3):732-5. PubMed ID: 17098427
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and SAR studies of a novel class of S1P1 receptor antagonists.
Nakamura T; Yonesu K; Mizuno Y; Suzuki C; Sakata Y; Takuwa Y; Nara F; Satoh S
Bioorg Med Chem; 2007 May; 15(10):3548-64. PubMed ID: 17379528
[TBL] [Abstract][Full Text] [Related]
14. SAR studies of 3-arylpropionic acids as potent and selective agonists of sphingosine-1-phosphate receptor-1 (S1P1) with enhanced pharmacokinetic properties.
Yan L; Huo P; Hale JJ; Mills SG; Hajdu R; Keohane CA; Rosenbach MJ; Milligan JA; Shei GJ; Chrebet G; Bergstrom J; Card D; Mandala SM
Bioorg Med Chem Lett; 2007 Feb; 17(3):828-31. PubMed ID: 17092714
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.
Cirillo R; Gillio Tos E; Schwarz MK; Quattropani A; Scheer A; Missotten M; Dorbais J; Nichols A; Borrelli F; Giachetti C; Golzio L; Marinelli P; Thomas RJ; Chevillard C; Laurent F; Portet K; Barberis C; Chollet A
J Pharmacol Exp Ther; 2003 Jul; 306(1):253-61. PubMed ID: 12660315
[TBL] [Abstract][Full Text] [Related]
16. Effects of gestational age on prostaglandin EP receptor expression and functional involvement during in vitro contraction of the guinea pig uterus.
Terry KK; Lebel WS; Riccardi KA; Grasser WA; Thompson DD; Paralkar VM
Prostaglandins Leukot Essent Fatty Acids; 2008 Jan; 78(1):3-10. PubMed ID: 18036799
[TBL] [Abstract][Full Text] [Related]
17. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.
Ohta H; Sato K; Murata N; Damirin A; Malchinkhuu E; Kon J; Kimura T; Tobo M; Yamazaki Y; Watanabe T; Yagi M; Sato M; Suzuki R; Murooka H; Sakai T; Nishitoba T; Im DS; Nochi H; Tamoto K; Tomura H; Okajima F
Mol Pharmacol; 2003 Oct; 64(4):994-1005. PubMed ID: 14500756
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and activity of small molecule GPR40 agonists.
Garrido DM; Corbett DF; Dwornik KA; Goetz AS; Littleton TR; McKeown SC; Mills WY; Smalley TL; Briscoe CP; Peat AJ
Bioorg Med Chem Lett; 2006 Apr; 16(7):1840-5. PubMed ID: 16439116
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 position.
Tucker TJ; Lumma WC; Lewis SD; Gardell SJ; Lucas BJ; Sisko JT; Lynch JJ; Lyle EA; Baskin EP; Woltmann RF; Appleby SD; Chen IW; Dancheck KB; Naylor-Olsen AM; Krueger JA; Cooper CM; Vacca JP
J Med Chem; 1997 Oct; 40(22):3687-93. PubMed ID: 9357536
[TBL] [Abstract][Full Text] [Related]
20. Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.
Quattropani A; Dorbais J; Covini D; Pittet PA; Colovray V; Thomas RJ; Coxhead R; Halazy S; Scheer A; Missotten M; Ayala G; Bradshaw C; De Raemy-Schenk AM; Nichols A; Cirillo R; Tos EG; Giachetti C; Golzio L; Marinelli P; Church DJ; Barberis C; Chollet A; Schwarz MK
J Med Chem; 2005 Dec; 48(24):7882-905. PubMed ID: 16302826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
